Laboratorio de Virología,1 Unidad de Hepatología, Hospital de Niños Ricardo Gutiérrez, C1425EFD Ciudad de Buenos Aires,3 Roche Molecular Systems, Buenos Aires, Argentina2
Received 6 March 2003/ Returned for modification 23 May 2003/ Accepted 22 October 2003
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
HCV infection in childhood has been studied less, mainly because of its initial asymptomatic course and thus the difficulty in reaching an accurate diagnosis early in life. The main risk factors for HCV transmission to children are maternal HCV infection and transfusion of blood or blood products. This latter issue has nearly disappeared since the introduction of improved blood-screening measures worldwide in 1992. Adolescents who were given a blood transfusion before 1992 are thus still at risk of developing posttransfusional hepatitis and its complications. Hence, perinatally acquired HCV and intravenous drug use are likely to be the only significant sources of pediatric and adolescent HCV infection, respectively (17).
The outcome of infection is extremely variable when acquired in childhood, and its natural history in children is still unknown. Long-term outcome is relevant in pediatric patients, as they may still be young adults after 20 to 40 years of infection. Furthermore, it is not feasible to predict in the early stages which patients have a more somber prognosis (16, 17). Nor is it known whether the risk of chronic disease is higher for patients infected at birth than for those infected at an older age. It has been documented that persistent infection develops in 85% of infected newborns, whereas chronic hepatitis and cirrhosis have been found in 70 and 20%, respectively, of those chronically infected (31). Furthermore, persistent viremia in children has been estimated to range from 45 to 86% of cases (16) and shown to remain relatively stable in one patient over time (4).
Considering the silent evolution of HCV infection in children, periodic screening of the infection has become mandatory to prevent liver complications and to predict which patients will develop a more aggressive disease (3, 16).
Several studies have evaluated the epidemiology of HCV infection in children and/or adults in Argentina (12, 14, 23, 24, 26-28), assessing the presence of HCV RNA in a single sample (1, 23, 26, 28).
The aim of the present study was to analyze exposure to HCV in 48 infants and children in Argentina and to evaluate consecutive samples in 26 of them to study the outcome of HCV infection in its early stages. As far as we have been able to ascertain, this is the first study in our region that evaluates a large pediatric cohort and furthermore contributes to the knowledge of the natural history of the infection by assessing biochemical and molecular parameters during a follow-up period longer than 24 months.
| MATERIALS AND METHODS |
|---|
|
|
|---|
HCV-infected infants and children were defined by the presence of (i) positive anti-HCV antibodies with a signal-to-cutoff ratio of
3.8 at or after 18 months of age (2) and/or (ii) positive HCV RNA on two or more separate occasions.
Patients were classified into two groups, and the demographic, clinical, and laboratory features are summarized in Table 1.
|
Samples were obtained at regular intervals during follow-up, which was initially every 3 months. After confirmation of HCV infection, samples were collected at longer intervals (6 to 12 months) to monitor HCV viremia. The follow-up period ranged from 3 to 107 months according to the age of the patient.
Anti-HCV antibodies were determined by third-generation HCV enzyme-linked immunosorbent assay (Ortho Diagnostics Systems, Raritan, N.J.).
Blood samples were obtained by vein puncture and collected in sterile tubes. Samples were centrifuged, and plasma was aliquoted in RNase-free tubes and frozen to -80°C within 3 h.
Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were determined by the International Federation of Clinical Chemistry and Laboratory Medicine method by using an autoanalyzer (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer's instructions. Normal ALT and AST levels were
32 and
48 IU/liter, respectively, when testing was done at 37°C.
RNA extraction and RT-PCR of 5'UTR. RNA was extracted from 200 µl of plasma with Trizol reagent (GIBCO BRL, Rockville, Md.) and chloroform. Two microliters of RNA MS2 (Roche Diagnostics) was added to the extraction reagent in each tube as an internal control prior to extraction. RNA was precipitated at -20°C with isopropyl alcohol and centrifuged for 30 min at 4°C. The pellet was washed with 800 µl of 75% ethanol, dried, and resuspended in 40 µl of sterile water. To evaluate the efficiency of extraction, 10 µl of RNA was subjected to agarose gel electrophoresis and ethidium bromide-stained MS2 RNA was observed under UV. Reverse transcription (RT)-nested PCR amplification of the 5' untranslated region (5'UTR) was performed in a Perkin Elmer GeneAmp PCR System 2400 thermocycler as previously described (14). Briefly, 10 µl of RNA was reverse transcribed and amplified by nested PCR with 5'UTR-specific primers. The primers used were as follows: for the first round, sense primer NF5 (5'-GTG AGG AAC TAC TGT CTT CAC GCA G) and antisense primer NR5 (5'-TGC TCA TGG TGC ACG GTC TAC GAG A) (GIBCO BRL); for the second round, sense primer KF2 (5'-TTC ACG CAG AAA GCG TCT AG) and antisense primer 211 (5'-CAC TCT CGA GCA CCC TAT CAG GCA GT) (GIBCO BRL). The RT-PCR mixture contained 50 mM KCl, 10 mM Tris-HCl (pH 8.4), 1.5 mM MgCl2, 0.16 mM (each) deoxynucleoside triphosphate, 0.4 µM (each) primer, 1 U of Taq DNA polymerase (Promega), and 2 U of Moloney murine leukemia virus retrotranscriptase (Promega). The second round was done under the same conditions, except for the Moloney murine leukemia virus retrotranscriptase, and with 5 µl of the first-round PCR product. The PCR protocol consisted of one cycle of RT at 42°C for 15 min, followed by the first PCR round at 95°C for 3 min, 30 cycles of 95°C for 1 min and 62°C for 1 min, and one cycle at 72°C for 7 min. The second round was done under the same conditions as the first round. Twenty microliters of the 251-bp second-round PCR product was observed under UV after electrophoresis on a 2% agarose gel containing ethidium bromide.
Negative results were retested by use of the RT-PCR-based AMPLICOR HCV test kit, version 2.0 (low detection level, 50 IU/ml) (Roche Molecular Systems), according to the manufacturer's instructions.
Restriction fragment length polymorphism analysis of 5'UTR amplicons. Five microliters of the amplicons was digested with restriction enzymes according to the method of Davidson et al. (9) with slight modifications. Briefly, amplicons were incubated separately with RsaI/HaeIII and HinfI/MvaI at 37°C for 4 h, and restriction products were subjected to 15% polyacrylamide gel electrophoresis to evaluate the genotype. To determine the viral subtype, amplicons were digested with BstUI at 60°C for 1 h (genotype 1) or ScrFI at 37°C for 4 h (genotypes 2 and 3) and further subjected to 12% polyacrylamide gel electrophoresis. Results were expressed as previously described (14).
Determination of HCV viral load. The HCV viral load was determined from a fresh plasma aliquot by using the RT-PCR-based AMPLICOR HCV MONITOR test, version 2.0 (linear range, 600 to 850,000 IU/ml) (Roche Molecular Systems), according to the manufacturer's instructions.
Avoidance of PCR contamination. To avoid PCR contamination, we used separate airflow cabinets for RNA extraction and RT-PCR. In addition, individual sets of micropipettes and aerosol-resistant tips were used for each procedure. Agarose gel electrophoresis was carried out in a separate room. We strictly followed the recommendations of Kwok and Higuchi (19).
| RESULTS |
|---|
|
|
|---|
3.8 in all patients. HCV viremia was assessed for all samples (Table 2). HCV viremia results were positive for 23 patients, occasionally positive for 8 patients, and negative for 17 patients. In particular, in group B, 15 patients had consecutive positive results and 3 patients had consecutive negative results for HCV viremia, whereas 8 patients had three additional viremia patterns. The first pattern was present in 5 of 8 patients who initially showed positive viremia which then became undetectable in subsequent samples (+/- pattern). The second pattern, observed in 1 of 8 patients, showed initially undetectable viremia that became positive in consecutive samples (-/+ pattern). In the third pattern, present in 2 of 8 patients, viremia fluctuated from positive to undetectable and again to positive during the follow-up period (intermittent pattern).
|
|
We also evaluated HCV viral load and both serum transaminase values during follow-up (Fig. 1). Despite the fact that patients were asymptomatic during our study, the levels of ALT and AST in serum were elevated in almost 50% of the cases. We also detected persistent high viremia levels in consecutive samples of children and infants, as determined by HCV viral load. Interestingly, we found higher levels of ALT and AST in patients with higher viremia than in those who had a low or undetectable HCV viral load. Among group B patients, 3 of 26 presented an undetectable viral load, although viremia was detected by RT-PCR, but this apparent discrepancy may be explained by the dissimilar sensitivities of the two methods used.
|
| DISCUSSION |
|---|
|
|
|---|
HCV viremia was evaluated in the 22 pediatric patients with one blood sample each (group A). The evaluation of HCV infection among these patients rendered 14 negative HCV viremia results from 5 children born to HCV-HIV-coinfected women, 2 cases of posttransfusional hepatitis under study, and 7 patients with sporadic anti-HCV positive antibodies (data not shown). HCV RNA-negative samples were retested with the more sensitive AMPLICOR assay, and reproducible results were rendered.
On the other hand, due to an exhaustive analysis of pediatric samples obtained during follow-up, we detected diverse patterns of HCV viremia in 26 patients from group B, ranging from persistently negative through intermittent patterns to persistently positive RT-PCR results. We confirmed fluctuating viremia in 8 patients free of treatment, as also previously described for adults and children (6, 12, 13, 15). Group B patients were thoroughly evaluated to determine the features of HCV infection in children and infants in our country and its evolution over time.
It is well documented that maternal HCV-HIV coinfection facilitates HCV transmission from mother to child. Recently, Yeung et al. (31) performed a meta-analysis of 8 studies on mother-to-child HCV transmission and established a weighted rate of vertical HCV transmission of 19.4% ± 2.0% among HCV-HIV-coinfected women. In our study, the majority of patients who became perinatally HCV infected were born to HCV-HIV-coinfected mothers, indicating that vertical HCV transmission is enhanced by maternal HIV coinfection.
In the present study, vertical HCV infection in children younger than 18 months was diagnosed by means of viremia evaluation in consecutive samples, since maternal anti-HCV antibodies may still be present until this age. However, it should be kept in mind that in perinatally infected patients, HCV RNA may be detected in serum at variable times after infection. For example, Dal Molin et al. detected HCV RNA 1 month after birth in an infant born to an HCV-positive mother (8), whereas Ketzinel-Gilad et al. observed positive HCV viremia as early as 2 days after delivery in other patients (18). Hence, the follow-up period proves to be crucial to reach an accurate diagnosis, mainly for perinatal HCV infection.
The genotype 1 predominance detected in our patients was in agreement with previous reports from our country (14, 23, 26) and from South America (21, 22, 25, 29). Surprisingly, genotype assignment was not feasible for 4 samples, due to a DNA restriction pattern with an extra restriction site, distinct from the one described by Davidson et al. (9). Future analysis of the HCV 5'UTR sequence will allow us to define the HCV genotype more accurately in such samples.
A helpful approach for the detection of HCV RNA in the population studied was the evaluation of HCV viral load, which is recommended worldwide for monitoring HCV therapy (16, 20). In this study, we used HCV viral load to evaluate the progression of HCV replication in the host. High levels of HCV viremia persisted in most pediatric patients during follow-up, proving similar to the ones reported by other authors for adult patients (30). These data demonstrate that HCV viral load is unrelated to patient age. Furthermore, we detected a higher mean HCV viral load in patients with continuously positive viremia than in those showing other HCV viremia patterns. Other authors have reported that HCV viral load and liver damage are largely independent in adults (11) and children (4). Thus, we believe that the high HCV viral load observed in our patients can hardly be a predictive factor of liver damage, as it mainly depends on the host's ability to control HCV replication.
The relationship between ALT and HCV viral load in adults and pediatric patients has been widely evaluated. In the present study, normal ALT and AST values were detected irrespective of the HCV viral load displayed. Thus, these biochemical markers of liver function fail to correlate with viral replication (Pearson r2, 0.07882; two-tailed P value, 0.1647). The absence of serum transaminases and viral load correlation was also reported in other studies of pediatric (4, 5) and adult (10) patients. However, we observed a trend to higher levels of serum transaminases in patients with increased viral loads, but further analysis of a larger cohort will be required for confirmation.
In conclusion, while chronic HCV infection in children and infants is depicted by a high rate of viral replication, the setting up of HCV infection may occur with fluctuating viremia. Thus, the existence of intermittent viremia in children and infants rules out using one blood sample as a diagnostic tool for the assessment of HCV infection and highlights the need for periodic HCV infection monitoring in childhood.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|